Emzor Group to Enhance Local Pharmaceutical Investment in Maternal Health
Emzor Group is set to intensify its investment in domestic pharmaceutical manufacturing and maternal health initiatives, as Nigeria grapples with one of the highest maternal mortality rates globally.
In recognition of the International Day of Maternal Health and Rights (IDMHR), the company has issued a warning regarding the ongoing public health crisis posed by preventable deaths during childbirth in Nigeria, the continent’s most populous nation.
Uzoma Ezeoke, Executive Director of Emzor, emphasized the organization’s vital role in addressing this issue, stating, “We proudly reaffirm our commitment to enhancing maternal health outcomes.” This commitment is increasingly critical as Nigeria contends with staggering maternal health challenges.
Kunle Faloye, Head of Marketing for MZO Group, noted the company’s contribution to the healthcare landscape. “We provide high-quality, affordable medications tailored to meet the specific health needs of mothers, ranging from nutrition and prenatal care to postnatal support,” he remarked. “Our local manufacturing initiatives aim to enhance accessibility, ensure a reliable supply, and ultimately improve health outcomes for both mothers and newborns, encompassing both over-the-counter supplements and prescription treatments.”
Data from the World Health Organization reveals that Nigeria faces approximately 993 maternal deaths per 100,000 live births, accounting for around one-third of global maternal fatalities. This alarming statistic translates to over 200 deaths daily, primarily due to preventable conditions like postpartum hemorrhage.
Emzor Group has announced plans to expand the production of crucial maternal health medications. This includes misoprostol-based treatments designed to mitigate excessive bleeding post-childbirth through its subsidiary, Zolon Healthcare Limited. The company’s locally produced drug, Eprostol, specifically targets postpartum hemorrhage, while another product, Mardox, addresses malaria in pregnant women—a major contributor to maternal anemia and low birth weight.
The company asserts that bolstering local production capacities will decrease reliance on imports, enhance supply reliability, and lower costs. These factors are paramount in low-resource environments where access to essential medications remains inconsistent.
The maternal health crisis in Nigeria is not solely attributed to medication shortages; it is also compounded by a frail primary healthcare system, a shortage of skilled birth attendants, and limited access in rural regions. While pharmaceutical solutions are vital, substantial reforms in healthcare delivery and funding are essential for achieving sustainable improvements.
“A comprehensive approach is necessary to improve maternal health, encompassing prevention, nutrition, and access to lifesaving medications,” added Ezeoke. “At Emzor, we are dedicated to fostering a future where no woman loses her life in childbirth and where both mothers and infants can realize their full potential.”
Further endorsing the group’s innovative strategies, Obiajulu Onwuzor, Head of Marketing at Zolon Healthcare, highlighted their commitment to quality. “We aim to deliver locally manufactured, quality-assured solutions aligned with clinical best practices. Strengthening our local production capabilities will help address the essential gap in access to maternal and child health medications,” he stated.
Emzor’s strategic direction aligns with a broader trend among Nigerian manufacturers aimed at localizing the production of vital medicines, a shift underscored by the need for more resilient medical supply chains across Africa, especially following recent global disruptions.
Celebrated annually on April 11, IDMHR highlights the need for equitable and respectful maternal care. This year’s theme, “Rights. Justice. Action. For all women and girls,” underscores the importance of eradicating preventable maternal deaths, strengthening midwifery systems, and championing women’s health rights, particularly in low-resource settings.
